HRAS Mutational Analysis
To identify point mutations in exons 2 and 3 of HRAS, a proto-oncogene that belongs to the family of Ras oncogenes, that is frequently mutated in bladder carcinomas, follicular thyroid carcinomas, and various sarcomas including malignant fibrous histiocytoma (MFH), leiomyosarcomas, rhabdomyosarcomas and dedifferentiated liposarcomas. Germline HRAS mutations are also identified in rare developmental disorder known as Costello syndrome. Assessment of the HRAS mutational status may identify patients likely to benefit from treatment by RAS inhibitors that are currently undergoing clinical trials.
Mutations are tested using PCR-based bi-directional DNA sequencing (Sanger sequencing) assay. This test is also available on Next Gen Sequencing platform.
Exons 2 and 3 are sequenced to detect mutations in codons 1 to 97 of HRAS. The lower limit of detection is approximately one cell bearing the mutation per five cells (20%).
Formalin-fixed, paraffin embedded tissue blocks or 10 unstained slides containing adequate amounts of tumor to be analyzed (see above sensitivity), with areas to be tested clearly indicated on the slides/block. Comparison of normal and tumor, or several different areas of tumor can be done, for an additional charge. Please provide a copy of the corresponding pathology report.
Additional charges may apply for tissue extraction.
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.